ES2967965T3 - Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes - Google Patents

Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes Download PDF

Info

Publication number
ES2967965T3
ES2967965T3 ES18731616T ES18731616T ES2967965T3 ES 2967965 T3 ES2967965 T3 ES 2967965T3 ES 18731616 T ES18731616 T ES 18731616T ES 18731616 T ES18731616 T ES 18731616T ES 2967965 T3 ES2967965 T3 ES 2967965T3
Authority
ES
Spain
Prior art keywords
antibody
antigen
binding fragment
patient
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18731616T
Other languages
English (en)
Spanish (es)
Inventor
Orly Adiv
Camille Bedrosian
Hagit Feldman
Alina Kurolap
Susan Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2967965T3 publication Critical patent/ES2967965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES18731616T 2017-05-22 2018-05-21 Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes Active ES2967965T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509576P 2017-05-22 2017-05-22
PCT/US2018/033678 WO2018217638A1 (en) 2017-05-22 2018-05-21 Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients

Publications (1)

Publication Number Publication Date
ES2967965T3 true ES2967965T3 (es) 2024-05-06

Family

ID=62620989

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18731616T Active ES2967965T3 (es) 2017-05-22 2018-05-21 Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes

Country Status (5)

Country Link
US (1) US11459382B2 (https=)
EP (1) EP3630819B1 (https=)
JP (1) JP7194698B2 (https=)
ES (1) ES2967965T3 (https=)
WO (1) WO2018217638A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7194698B2 (ja) 2017-05-22 2022-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与
JP7798763B2 (ja) * 2019-10-25 2026-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５関連疾患の治療または予防のための投与レジメン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20190256915A1 (en) * 2016-09-14 2019-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease
JP7194698B2 (ja) 2017-05-22 2022-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与

Also Published As

Publication number Publication date
WO2018217638A1 (en) 2018-11-29
EP3630819A1 (en) 2020-04-08
US20200172603A1 (en) 2020-06-04
US11459382B2 (en) 2022-10-04
JP2020520905A (ja) 2020-07-16
EP3630819B1 (en) 2023-10-11
JP7194698B2 (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
ES2965283T3 (es) Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
ES2589302T3 (es) Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib
WO2019028367A1 (en) METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
BR112020008182A2 (pt) dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
US20120189632A1 (en) Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
ES2967965T3 (es) Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes
JP2024016237A (ja) 活動性好酸球性食道炎を治療する方法
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
WO2021004494A1 (zh) 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用
Davis et al. Adalimumab for the treatment of Crohn‐like colitis and enteritis in glycogen storage disease type Ib
ES2383103T3 (es) Estrategia terapéutica para tratar enfermedades autoinmunitarias y degenerativas
WO2024206341A1 (en) Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
Abazi-Emini et al. Anti-factor h antibody-associated atypical hemolytic uremic syndrome: A case report
WO2024011251A9 (en) Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist
Özdemir Subcutaneous immunoglobulin replacement therapy experience with intravenous preparation
Shoman Insight into gastrointestinal manifestations of some pediatric autoinflammatory disorders
Ushimaru et al. Tubulointerstitial Nephritis Associated with Enteritis and Sacroiliitis
WO2026022216A1 (en) Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
Valluri et al. Acute Pancreatitis, A Rare Non-Hematological Adverse Event in a Patient Treated with Inj. Carfilzomib for Relapsed Multiple Myeloma Post Autologous Stem Cell Transplant
Mallikarjun Kalashetty et al. Hemophagocytic Lymphohistiocytosis in a case of Enteric Fever
CN118946366A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2007037788A1 (en) Antibody composition and passive immunization against pregnancy-induced hypertension using antidigoxin antibody (digibind)
Villajos et al. Non-celiac villous atrophy: More confusion or a new syndrome?
Hoque et al. Ulcerative Colitis in a Bangladeshi Child: A Case Report
TW202302632A (zh) 用於治療敗血症之方法及組合物